QNTM QNTM
Company Profile ↓Company Overview
QNTM (QNTM) is a publicly traded company listed on with a market capitalization of $11.27M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.27.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -89.57% |
| 6 Months: | -28.04% |
| 3 Months: | -45.90% |
| 1 Month: | -12.65% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.56 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 90.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 3.39M | 4.91M | 4.66M | 2.36M | 2.91M |
| Operating Income | - | -3.39M | -4.91M | -4.66M | -2.36M | -2.91M |
| EBITDA | - | -8.26M | -9.39M | -4.50M | -3.65M | -13.58M |
| Interest Expense | - | 350.62K | 235.57K | 105.08K | -72.62K | 45.18K |
| Pretax Income | - | -8.74M | -9.77M | -4.75M | -3.70M | -13.75M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -8.58M | -9.25M | -5.32M | -3.03M | -13.56M |
| Diluted EPS | - | -3.53 | -3.23 | -1.25 | - | -3.06 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 27.43M | 19.57M | 15.88M | 15.32M |
| Operating Income | - | -27.43M | -19.57M | -15.88M | -15.32M |
| EBITDA | - | -22.12M | -15.72M | -14.38M | -25.79M |
| Interest Expense | - | 48.82K | 299 | 47.58K | 618.64K |
| Pretax Income | - | -26.70M | -18.23M | -14.92M | -26.96M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -23.61M | -17.90M | -14.20M | -26.18M |
| Diluted EPS | - | -39.61 | -29.93 | -13.12 | -8.20 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 38.41M | 17.47M | 17.12M | 11.16M |
| Current Assets | - | 17.85M | 11.09M | 12.05M | 6.48M |
| Cash & Equivalents | - | 16.98M | 2.76M | 6.00M | 1.91M |
| Inventory | - | - | 0 | 117.24K | 52.13K |
| Receivables | - | 374.38K | 7.42M | 3.81M | 231.05K |
| Total Liabilities | - | 7.87M | 4.57M | 6.68M | 6.06M |
| Current Liabilities | - | 7.83M | 4.57M | 6.68M | 6.06M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 516.42K | 339.20K | 824.92K | 1.88M |
| Total Equity | - | 30.54M | 13.24M | 11.48M | 6.92M |
| Shares Outstanding | - | 592.37K | 605.80K | 2.30M | 3.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -28.33M | -10.83M | -6.88M | -8.24M |
| Investing Cash Flow | - | 12.12M | -269.58K | -1.50M | -1.95M |
| Financing Cash Flow | - | -2.07M | -3.13M | 11.62M | 6.10M |
| Capital Expenditure | -500.00K | -363.96K | - | - | - |
| Free Cash Flow | - | -28.70M | -10.83M | -6.88M | -8.24M |
| Net Change in Cash | - | -18.28M | -14.22M | 3.24M | -4.09M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -77.3% | -135.2% | -123.7% | -378.0% |
| ROCE % | - | -89.7% | -151.6% | -152.1% | -300.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QNTM
Quantum BioPharma’s MS drug targets myelin as phase 2 nears - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSzRCeno1UWlEd2dQM2t4eHlKNS1IVVd1MkdCcUZZNWl2TmJibVAtSnl3MW9xU0dycE1VRnEwQmNaTC1pLWR1dS1TZUxWVUFucXkwZ3Q0NV9jNF9UaWVYblNGQmkzaUhGaUVjVVNhNWxOOFI2b0ZnS2VmUXdhbWlBeTRwOXNGSFdKcjh6U0…
Quantum BioPharma Ltd. Closes CAD$123,487.43 Debt Settlement Through Share Issuance - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxON2xfOElZcTZ6LXJGVU4xWUNyaXhMd1JHMkpER2RWWjA3a1FNdEtDN2JMNFA5T05uTlprTDZ3dkZ1a09xaThlWUVrN2JvdERLTkY4aU56anFrVTN2TmFXVnJUa2tXYjJVcExoT2JmMVcwekpFWExJLTNRcUZ4U1hkeS1MaDREZkcwbENVaF…
Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNaDhMazRVSTRKRFFKaVJwMEUzcGNnSHE5bV9PaURvWVFQNUwyQl9ZZkdBNFBXZGVpMF9NMldTcTRiSjhqbzhiaHhaZ1dQdGhaYUtGazFmSzlZd3Yway1xcHRzOThlMFFNQlJPUFhsZkFnQ0dCaUF4N3p0N000UkVXcUYwckZkSUJfaXNZS3…
Why Did QNTM Stock Pop In Pre-Market Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNXzZOeWtlWHNHbVc1UW5sUkpVY0x2QzV0bHpwaFpBNDU5QllmYTV0WV9ZdGZzVkZSbHVaMDR2WnNlY0NBVENzTFpYaDJ3NDMySEttWHJOMFpMZjlvNWk0SFRHR1FPZWg0bHRlQUFqclplZS0yaW50UUw2dXJ2UWFZMlh5VmVIVTRYamVfOE…
QNTM Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE9wSkV4UE9taS16M3pkQVdial91VU82ckRRNnJSWGZDbWl3MDRaVFR5SG0xVXV2MFNNamd5ampETFlvdTY3WU96VjFEQVFZbzRHY091aTZvVE1NQjFxQ3c?oc=5" target="_blank">QNTM Should I Buy</a> <font c…
Quantum BioPharma stock surges on MS imaging study progress - Investing.com
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQR3dFcEZrQ1JUdVFLTk5mcnhMV1NqNEV2WUhoNU5QU0V4WEtJbjB3LXNYeEc0di1oZXoxaFJyS0VMdWRrZUFXa3ZOenhxaXpOTUdUdkhuRFVVeGhIU0Z3dW53QVFnSEFaV29WUG9pMVJSTzJrcm52NXRjSUxtWmotRW9pa3d4b2QxZ0kyLV…
QNTM — Frequently Asked Questions
What is the current share price of QNTM?
As of 2026-08-05 17:25 PDT, QNTM trades at $2.90 on NASDAQ/NYSE. Its 52-week range is $2.10 to $29.21.
What is the market capitalisation of QNTM?
QNTM has a market capitalisation of $11.27M on NASDAQ/NYSE.
What is the P/E ratio of QNTM?
QNTM trades at a trailing price-to-earnings (P/E) ratio of -0.35. Its price-to-book (P/B) ratio is 1.63.
Is QNTM a good stock to buy?
This page provides a data-driven analysis of QNTM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.